Autolus Therapeutics’ (AUTL) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTL) in a research report sent to investors on Monday,Benzinga reports. They currently have a $10.00 price target on the stock.

Other analysts also recently issued reports about the company. Redburn Atlantic upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a research note on Friday, November 15th. The Goldman Sachs Group upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the company from $7.00 to $7.60 in a research note on Monday, November 18th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $10.40.

Autolus Therapeutics Trading Down 2.5 %

Shares of NASDAQ AUTL opened at $2.30 on Monday. Autolus Therapeutics has a 12 month low of $2.07 and a 12 month high of $7.37. The stock has a 50 day moving average of $2.83 and a 200-day moving average of $3.60. The company has a market capitalization of $612.02 million, a P/E ratio of -1.90 and a beta of 2.05.

Autolus Therapeutics (NASDAQ:AUTL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period in the prior year, the company posted ($0.26) earnings per share. Analysts predict that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Institutional Trading of Autolus Therapeutics

A number of institutional investors have recently modified their holdings of AUTL. Daiwa Securities Group Inc. lifted its position in shares of Autolus Therapeutics by 2,659.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock valued at $55,000 after acquiring an additional 15,293 shares during the period. Renaissance Technologies LLC lifted its position in shares of Autolus Therapeutics by 253.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,145,056 shares of the company’s stock valued at $3,985,000 after acquiring an additional 821,156 shares during the period. ProShare Advisors LLC bought a new stake in shares of Autolus Therapeutics during the 2nd quarter valued at $43,000. HighVista Strategies LLC lifted its position in shares of Autolus Therapeutics by 98.5% during the 2nd quarter. HighVista Strategies LLC now owns 518,820 shares of the company’s stock valued at $1,805,000 after acquiring an additional 257,496 shares during the period. Finally, Great Point Partners LLC raised its holdings in shares of Autolus Therapeutics by 195.0% during the 2nd quarter. Great Point Partners LLC now owns 3,441,667 shares of the company’s stock worth $11,977,000 after buying an additional 2,275,000 shares in the last quarter. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.